Boswellia for joint pain: evidence, forms and precautions

Oral Boswellia may modestly reduce pain and functional difficulty in some people with knee osteoarthritis, but study quality and size remain limited. A meta-analysis of seven randomized trials including 545 people found favorable signals for pain, stiffness and function, while also reporting bias, product heterogeneity and generally moderate-to-low quality.

The finding concerns symptomatic relief studied over limited periods. Available data do not show that Boswellia changes osteoarthritis progression or repairs cartilage. It should not replace assessment and care for persistent joint pain.

Raw resin, a standardized oral extract and a topical preparation are not interchangeable: trials did not test the same products. Resin is the raw material; a standardized extract aims to specify composition; a cream or balm is applied to skin. The percentage of boswellic acids or AKBA alone does not prove that a product works better.

Most clinical results concern oral use of particular extracts. NCCIH says topical use has been studied, but evidence is insufficient to conclude that it works for osteoarthritis.

The available studies mainly report digestive symptoms. Evidence on interactions is not sufficient to announce a specific interaction with a named medicine; people taking medicines should seek professional advice.

Check the species, plant part, extract amount and any standardization statement. Compare those details rather than milligrams alone. There is no universal dose to infer from these studies.

The French site also covers curcumin forms and ginkgo interactions.